DUBLIN, IRELAND & LONDON, UK — December 8, 2025 — Ayrmid Ltd., parent company of Gamida Cell Inc., announced additional positive clinical results for Omisirge® (omidubicel-onlv), its advanced stem cell transplant therapy for Severe Aplastic Anemia (SAA). Presented at the 67th ASH Annual Meeting, the new data show 94% disease-free and overall survival, 95% rapid neutrophil recovery, and no severe acute or chronic GVHD, highlighting the therapy’s transformative potential for patients with limited treatment options. The results further support the therapy’s recent FDA approval on December 5, 2025, marking it as the first cell therapy approved for SAA.
Science Significance
The newly presented Phase 2 findings reinforce the scientific strength of Omisirge, demonstrating remarkably fast neutrophil recovery with a median of 8 days, alongside rapid immune reconstitution and a 94% survival rate. These outcomes indicate that Omisirge’s engineered stem cell graft delivers enhanced engraftment kinetics and reduced graft-related complications, addressing longstanding biological barriers in treating high-risk SAA. In a population with historically poor outcomes, the study’s absence of severe acute or chronic GVHD represents a major scientific breakthrough, validating the platform’s high-precision cell-therapy biology.
Regulatory Significance
The compelling efficacy and safety results presented at ASH strengthen the regulatory foundation underlying Omisirge’s recent FDA approval, making it the first cell therapy authorized for SAA in both adults and pediatric patients aged six and older. The new data further justify the therapy’s regulatory pathway, demonstrating outcomes that surpass many standard transplant benchmarks. As agencies increasingly emphasize safety, durability, and post-transplant recovery, Omisirge’s performance bolsters confidence in advanced cell-therapy frameworks, supporting future submissions and potentially informing regulatory guidance for allogeneic engineered grafts.
Business Significance
Advertisement
Ayrmid’s expanding clinical evidence base significantly enhances the commercial prospects of Omisirge within the global hematology and transplant markets. Demonstrating superior outcomes in a rare and underserved indication boosts physician confidence, payer interest, and institutional adoption. As a company with two FDA-approved cell therapies on the market, Ayrmid’s strengthened data package supports long-term revenue growth, competitive positioning, and potential partnership opportunities in the rapidly expanding cell and gene therapy sector. The positive results also reinforce Gamida Cell’s role as a leader in next-generation graft engineering.
Patients’ Significance
For patients with Severe Aplastic Anemia, especially those lacking matched sibling donors, the results represent major therapeutic hope. With 95% achieving neutrophil recovery and no cases of severe GVHD, Omisirge demonstrates the potential to radically improve clinical outcomes and quality of life. Faster engraftment reduces life-threatening infection risk, while the reduced incidence of GVHD translates to a safer, more predictable post-transplant recovery. Patients who previously faced limited, risky, or ineffective options may now access a therapy designed to expand transplant eligibility and provide a viable path toward long-term remission.
Policy Significance
The rapid approval and strong real-world-aligned clinical data for Omisirge highlight the growing importance of advanced cellular therapies within national and international healthcare policy frameworks. As policymakers refine standards for ATMP oversight, reimbursement structures, and transplant accessibility, therapies like Omisirge set new benchmarks for safety, effectiveness, and equity in rare-disease treatment. The results underscore the necessity for continued regulatory modernization, cross-border alignment, and sustained investment in cell-therapy infrastructure to broaden access for underserved patient populations.
The new ASH 2025 data reinforce Omisirge’s position as a breakthrough therapy for Severe Aplastic Anemia, combining exceptional engraftment performance, survival outcomes, and safety results. With FDA approval secured and clinical evidence continuing to accumulate, Ayrmid and Gamida Cell are now positioned to accelerate global access to this transformative therapy. As Omisirge moves into broader clinical use, it stands to redefine transplant standards and deliver meaningful advances for patients facing one of hematology’s most critical unmet needs.
Source: Ayrmid Pharma Ltd press release
